What To Know
- The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting.
- We expect this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.
Oncimmune Holdings plc today announces that it has signed a foothill contract to utilize the Company’s EarlyCDT Lung panel to detect incident lung cancer cases in a screening setting.
With one of the world’s largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting.
We expect this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.
Adam M Hill, CEO of Oncimmune said: “Over the past two months we have announced commercial contracts which touch upon the full breadth of Oncimmune’s commercial offering. Our three-year strategy, announced in late 2018, centered on identifying and capitalizing upon the wide range of opportunities presented by Oncimmune’s proprietary autoantibody-based platform. We firmly believe that the momentum we are building validates our strategy and underpins the commercial potential of our business.
We look forward to delivering this work over the coming weeks and announcing the further development of this partnership.”